CTRI/2024/08/072453尚未招募3 期
A Prospective, Randomized, Double-blinded, Multi-centric, Two-arm, Parallel-group, Active-Controlled, Phase III Study to Assess the Efficacyand Safety of Cetirizine Ophthalmic in Patients having ocular itching associated with allergic conjunctivitis - NI
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 Aged between 18 years to 75 years of both gender
- •2 Patient with signs and symptoms of allergic conjunctivitis diagnosed clinically
- •3 Subjects must have an ocular itching score 0
- •4 Patient is willing to give informed consent able to provide availability for the entire study period and follow study protocol
排除标准
- •Patients with bacterial chlamydial viral and membranous conjunctivitis
- •Patients with ocular surface disorders like pterygium dry eye were excluded from the study.
- •Patients with history of uveitis blepharitis herpes simplex keratitis or herpes zoster keratitis.
- •Patients with history of retinal detachment diabetic retinopathy and progressive retinal disease
- •Patients with history of glaucoma or Intraocular Pressure over 25mmHg at the screening visit, or a history of elevated IOP within the past 1year.
- •Patients with ocular surgery or refractory surgery within 6 months prior to visit 1 or planning to do a surgery during the trial.
- •Patients with use of antibiotics, antivirals, or topical cyclosporine, depot corticosteroids, NSAIDS and other antihistamines or mast cell stabilisers within 1 month of the screening visit.
- •Patients unwilling not to wear contact lenses during the study.
- •Pregnant and lactating women
- •Patient with history of hereditary degenerative retinal disorders eg retinitis pigmentosa or ischemic optic neuropathy including nonarteritic anterior ischemic optic neuropathy
- •Patient with history of bleeding disorders or significant active peptic ulceration
- •Patient with history of cancer or undergoing cancer chemo or radiotherapy
- •Patient having hypersensitivity or any other contraindication to any of the Investigational products including its components; or history of hypersensitivity reaction to sulfa drugs
- •Patient who have participated in another Investigational study within the 3 months prior to enrolment in this study
- •Investigator, study personnel, sponsor representatives and their first-degree relatives
研究者
相似试验
已完成
不适用
An evaluation of the benefits of frequent optimisation using QuickOpt in patients with Cardiac Resynchronisation Therapy Defibrillator Device (CRT-D)ife-threatening ventricular arrhythmiasLife-threatening ventricular arrhythmiasCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemACTRN12610000051044St. Jude Medical1,500
已完成
不适用
To assess the efficacy and safety of an Immunostimulant supplement on the immunity of healthy human subjectsCTRI/2021/07/035206OmniActive Health Technologies30
已完成
不适用
A prospective, randomized, double-blind, multiple dose, parallel, placebo-controlled, clinical interventional study.CTRI/2021/01/030493OmniActive Health Technologies
招募中
1 期
A Prospective, double-blind, randomized, single centre trial to evaluate the rate of RAAS inhibitor withdrawal or down-titration in non-dialysis patients with CKD stage IIIB to Vrandomized to Patiromer or placeboCTIS2023-503984-41-00Mario Negri Institute For Pharmacological Research IRCCS1
进行中（未招募）
不适用
Phase IIb safety and efficacy study of different oral doses of BAY 94-8862 in subjects with worsening chronic heart failure and left ventricular systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney disease aloneSubjects with worsening chronic heart failure (WCHF) and left ventricular systolic dysfunction and either type 2 diabetes mellitus (DM type 2) with or without chronic kidney disease (CKD) or moderate chronic kidney disease aloneMedDRA version: 16.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 16.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861MedDRA version: 16.1Level: LLTClassification code 10066498Term: Cardiac failure chronic aggravatedSystem Organ Class: 100000004849EUCTR2012-002627-15-NLBayer HealthCare AG1,510